SCHEMBL3058865

SCHEMBL3058865

COc1cc(OC)c(OC)cc1CN1CCc2cc(S(N)(=O)=O)c(OC)cc2C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.59
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
CA7 P43166 1/20 0.52
KDM4E B2RXH2 6/20 0.52
MAPT P10636 3/20 0.52
TSHR P16473 2/20 0.52
ABCB1 P08183 5/20 0.52
DHFR P00374 1/20 0.52
TDP1 Q9NUW8 1/20 0.50
GAA P10253 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 3/20 0.48
ALOX15 P16050 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ABCC1 P33527 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3045905 0.87 KDM4E (0.52) CA2CA9KDM4EMAPTTSHR
SCHEMBL3051373 0.86 DRD3 (0.54) POLBCA2CA9KDM4EMAPT
SCHEMBL3056068 0.84 KDM4E (0.62) CA2CA9CA7KDM4EMAPT
SCHEMBL3056516 0.84 KDM4E (0.66) CA2CA9KDM4EMAPTABCB1
SCHEMBL3058767 0.84 KDM4E (0.55) CA2CA9KDM4EMAPTTSHR
SCHEMBL3064371 0.83 CA9 (0.76) CA2CA9CA7KDM4EMAPT
SCHEMBL3046471 0.83 CA2 (0.60) CA2CA9CA7KDM4EMAPT
SCHEMBL3061675 0.83 REV1 (0.61) CA2CA9KDM4EMAPTABCB1
SCHEMBL3048961 0.82 ABCB1 (0.69) CA2CA9KDM4EABCB1TDP1
SCHEMBL3058965 0.82 CA2 (0.67) POLBCA2CA9KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394825-B2 Compound STERIX LIMITED (GB) 2013-03-12 US claimed
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US claimed
EP-2155192-B1 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LTD (GB) 2016-09-28 EP disclosed
US-8394825-B2 Compound STERIX LIMITED (GB) 2013-03-12 US disclosed
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US disclosed
EP-2155192-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS Sterix Limited (GB) 2010-02-24 EP disclosed
WO-2008117061-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LIMITED (GB) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222299-A1 COMPOUND MKI67, VHL, MYC POLB 3243/4885CA2 1077/4885CA9 1002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.